Mahagra 100mg

Mahagra 100 mg is the pharmaceutical drug formulated for the treatment of erectile dysfunction issues. Mahagra 100 mg is a brand of sildenafil citrate, a phosphodiesterase‑5 (PDE‑5) inhibitor that is mainly used for erectile dysfunction. It works by boosting nitric‑oxide‑mediated blood flow to the penis when you’re sexually aroused. 

Key Features

 How does Mahagra work?

Mahagra contains sildenafil, a phosphodiesterase‑5 (PDE‑5) inhibitor. During sexual stimulation, nitric oxide (NO) is released in the corpora cavernosa, raising cyclic‑GMP levels. PDE‑5 normally breaks down cGMP, thus, sildenafil blocks this enzyme, allowing cGMP to build up, relax smooth muscle, and increase blood flow to the penis.

• PDE5 inhibition: Mahagra includes Sildenafil Citrate, which selectively inhibits phosphodiesterase type 5 (PDE5) enzyme.
• Increased cGMP levels: PDE5 inhibition results in elevated levels of cyclic guanosine monophosphate (cGMP) in the penis.
• Smooth muscle relaxation: cGMP induces smooth muscle relaxation, enabling the blood vessels to dilate.
• Increased blood flow: Vascular dilation increases blood flow to the penis, facilitating an erection.

Usages

• Main treatment of erectile dysfunction.
• Sometimes prescribed off‑label for premature ejaculation when combined with other agents.

Dosage 

• Starting dose: 50 mg taken approx.1 hour before sexual activity.
• Dosage Adjustment: The dose can be decreased to 25 mg or increased to 100 mg based on efficacy and tolerability.
• Frequency: No more than one dose per 24 h.
• Special populations: 25 mg is recommended for patients >65 y, hepatic impairment, severe renal impairment, or those on strong CYP3A4 inhibitors.

Side‑effects

• Headache
• Flushing
• Dyspepsia
• Nasal congestion
• Abnormal vision
• Back pain
• Myalgia
• Nausea
• Dizziness
• Rash
• Priapism

Drug interactions 

• Nitrates contraindicated (dangerous hypotension).
• α‑blockers initiate sildenafil at the lowest dose, monitor blood pressure.
• CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin) increase sildenafil exposure; consider 25 mg start.
• Riociguat, vericiguat avoid concomitant use.

Pharmacokinetics 

• Absorption: Rapid; oral bioavailability approx. 40 % (range 25‑63 %).
• Onset: 30‑60 min; peak plasma approx. 1 h.
• Metabolism: Hepatic via CYP3A4 (major) and CYP2C9; active N‑dimethyl metabolite contributes approx. 40 % of activity.
• Half‑life: approx. 4 h for both parent and metabolite.
• Elimination: Mostly hepatic; renal clearance minimal; dose adjustment needed in severe renal impairment.

Efficacy

• The Phase III trial comparing sildenafil oral film (25 mg – 100 mg) with placebo demonstrated a clear benefit for the 100 mg dose.
• At 12 weeks, patients receiving the 100 mg film had a statistically significant increase in erectile function based on the IIEF‑EF score and a higher percentage of yes responses to the SEP‑3 question relating to successful intercourse compared to placebo.
• In fact, the study also remarked that the flexible‑dose design allowed participants to titrate up to 100 mg if necessary, and most who achieved that level reported favorable outcomes.

Safety

• Across the 12‑week treatment period, the 100 mg dose was well‑tolerated. The most common TEAEs were headache and dizziness, occurring at rates similar to placebo.
• A larger review of safety in 67 double‑blind, placebo‑controlled trials involving more than 14,000 men, similarly confirmed that sildenafil at 50 and 100 mg has an adverse‑event profile comparable in its type and frequency, with mild‑to‑moderate adverse events including flushing, dyspepsia, and visual changes, serious events included priapism or cardiovascular complications, though rarely.

Important considerations 

• Effectiveness: 100 mg sildenafil oral film results in clinically meaningful improvements in erections and intercourse success.
• Tolerability: The 100-mg dose shows a safety profile in keeping with the well-established sildenafil data-mostly mild side effects, low discontinuation rates.

Precautions 

• History of cardiovascular disease, recent MI/stroke, uncontrolled hypertension or hypotension.
• Penile anatomical deformities (Peyronie’s disease) or conditions predisposing to priapism: sickle‑cell anemia, multiple myeloma, leukemia.
• Avoid alcohol and grapefruit juice (can increase side‑effects). Pregnancy/lactation: not indicated for women.

Conclusion

Mahagra 100 mg is a potent PDE-5 inhibitor in treating ED by enhancing the NO-cGMP pathway, thus ensuring adequate penile blood flow. Safety depends on proper dosing, recognizing contraindications, particularly nitrates, and watching for rare but serious side effects. Always discuss your full medication list and medical history with a healthcare professional before starting.

References

https://www.ncbi.nlm.nih.gov/books/NBK558978/

https://pubmed.ncbi.nlm.nih.gov/19817982/

FAQ’s